Latest News and Press Releases

ZyVersa welcomes one-on-one meetings at the HCW Kidney Conference on July 15, 2024.

ZyVersa is on track to achieve key development milestones over the next 3 quarters.

Dublin, March 25, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Kidney Disease Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The diabetic kidney disease market size...

Initiation of Phase 2a trial first half 2024 with Cholesterol Efflux Mediator VAR 200 in diabetic kidney disease is a key milestone for ZyVersa.

EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Since 2019, audited records of chronic kidney disease (CKD) non-dialysis patients has revealed an ongoing, annual uptick in the proportion of...

ZyVersa engages CRO, George Clinical, to manage its P2a clinical trial with VAR 200 in Diabetic Kidney Disease expected to begin Q1-2024.

Plasma NLRP3 inflammasomes are significantly elevated in early-stage diabetic kidney disease, and levels progressively increase as kidney function worsens.

New York, Oct. 19, 2023 (GLOBE NEWSWIRE) -- In 2022, global revenue for Diabetic Nephropathy reached approximately $2.37 billion, projected to grow at a 6.70% CAGR, hitting $4.86 billion by 2033. It...

Cholesterol Transport Mediator™ VAR 200 is in development to reduce renal cholesterol and lipid accumulation that damages the kidneys' filtration system in patients with glomerular diseases, including...

Published data demonstrate that a deficiency in cholesterol transporter ABCA1 increases deposition of cellular cholesterol, contributing to inflammation, cell death (apoptosis), and damage to the...